Want to see CLRB full AI Analyst Report?
CLRB Stock Chart & Stats
$3.29
-$0.03(-9.33%)
At close: 4:00 PM EST
$3.29
-$0.03(-9.33%)
Day’s Range― - ―
52-Week Range$2.20 - $6.52
Previous CloseN/A
Volume1.30M
Average Volume (3M)128.81K
Market Cap
$20.06M
Enterprise Value$5.85
Total Cash (Recent Filing)$8.35M
Total Debt (Recent Filing)$1.53M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Aug 19, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.38
Shares Outstanding7,991,812
10 Day Avg. Volume123,088
30 Day Avg. Volume128,814
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.50Price Target Upside249.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Lead Asset Clinical EfficacyRobust 12‑month efficacy establishes a durable clinical signal for iopofosine, supporting regulatory filings and commercial differentiation in relapsed/refractory WM. High ORR and durable responses lower binary development risk and improve probability of accelerated approval and uptake if Phase III confirms results.
Clear Regulatory PathwayBreakthrough designation and an articulated accelerated approval plus randomized Phase III strategy create a structured regulatory roadmap. This reduces regulatory uncertainty, enables prioritized FDA engagement, and shortens time to potential market access if pivotal endpoints are met, strengthening strategic planning.
Material Financing To Fund DevelopmentAn oversubscribed financing that provides upfront capital and contingent milestone funding materially extends runway to support late‑stage development and initial commercialization planning. This reduces immediate liquidity pressure and permits focus on executing the Phase III and CLR125 programs.
Bears Say
Pre‑revenue Business ModelThe company remains pre‑revenue with persistent net losses and negative operating cash flow, meaning ongoing operations rely entirely on financing events. This structural lack of internal cash generation increases financing dependency and magnifies dilution risk if clinical or regulatory milestones slip.
Contingent Financing RiskA large portion of committed capital is contingent on clinical/regulatory milestones and market‑performance conditions, plus shareholder approvals. This creates execution and market risk to realize full funding, potentially leaving gaps if milestones miss timing or stock conditions are unmet.
Eroded Equity / Limited Balance Sheet CushionMaterial decline in shareholder equity and episodic negative equity reflect cumulative losses and dilution, reducing capital resilience. A thin equity cushion limits downside protection and increases the likelihood of future dilutive financings if trial timelines or revenue assumptions are delayed.
Cellectar Biosciences News
CLRB FAQ
What was Cellectar Biosciences Inc’s price range in the past 12 months?
Cellectar Biosciences Inc lowest stock price was $2.20 and its highest was $6.52 in the past 12 months.
What is Cellectar Biosciences Inc’s market cap?
Cellectar Biosciences Inc’s market cap is $20.06M.
When is Cellectar Biosciences Inc’s upcoming earnings report date?
Cellectar Biosciences Inc’s upcoming earnings report date is Aug 19, 2026 which is in 29 days.
How were Cellectar Biosciences Inc’s earnings last quarter?
Cellectar Biosciences Inc released its earnings results on May 14, 2026. The company reported -$1.33 earnings per share for the quarter, beating the consensus estimate of -$1.885 by $0.555.
Is Cellectar Biosciences Inc overvalued?
According to Wall Street analysts Cellectar Biosciences Inc’s price is currently Undervalued.
Does Cellectar Biosciences Inc pay dividends?
Cellectar Biosciences Inc does not currently pay dividends.
What is Cellectar Biosciences Inc’s EPS estimate?
Cellectar Biosciences Inc’s EPS estimate is -0.52.
How many shares outstanding does Cellectar Biosciences Inc have?
Cellectar Biosciences Inc has 7,991,812 shares outstanding.
What happened to Cellectar Biosciences Inc’s price movement after its last earnings report?
Cellectar Biosciences Inc reported an EPS of -$1.33 in its last earnings report, beating expectations of -$1.885. Following the earnings report the stock price went up 8.844%.
Which hedge fund is a major shareholder of Cellectar Biosciences Inc?
Currently, no hedge funds are holding shares in CLRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectar Biosciences Inc
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
CLRB Stock 12 Month Forecast
Average Price Target
$11.50
▲(249.54% Upside)
Technical Analysis
Ownership Overview
1.15% Insiders
1.38% Mutual Funds
1.56% Other Institutional Investors
91.83% Public Companies and
Individual Investors